BioSpace Insights
The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
Latest from Insights
BioSpace sits down with four NextGen companies that are thriving despite a multi-year down period. You will hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out. Watch now.
Surviving and Thriving in the Never-ending Biotech Downturn
LIVE WEBINAR | MAY 20 | 2PM–3PM EST
The rumors of biotech’s return have been greatly exaggerated. Despite some M&A sparks, a handful of mega fundraises and a trickle of IPOs, the biotech industry continues to climb out of a multi-year down period. So how does a company thrive in this environment?
BioSpace sits down with four NextGen companies doing just that, to hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out.
LIVE WEBINAR | MAY 20 | 2PM–3PM EST
The rumors of biotech’s return have been greatly exaggerated. Despite some M&A sparks, a handful of mega fundraises and a trickle of IPOs, the biotech industry continues to climb out of a multi-year down period. So how does a company thrive in this environment?
BioSpace sits down with four NextGen companies doing just that, to hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out.
LIVE WEBINAR | JUNE 25 | 11AM - 12PM ET
Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the fast-evolving life science landscape, AI is no longer a luxury—it’s a necessity. Join our exclusive webinar to discover how cutting-edge AI tools empower R&D teams, IP strategists, and innovation leaders.
Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the fast-evolving life science landscape, AI is no longer a luxury—it’s a necessity. Join our exclusive webinar to discover how cutting-edge AI tools empower R&D teams, IP strategists, and innovation leaders.
Listen to Denatured
Unravel the business of science with BioSpace.
In this episode of Denatured, presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses how AI transformation can help organizations navigate a rapidly evolving regulatory environment with senior director of regulatory innovation and technology, Michelle Gyzen.
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the importance of target product profiles, particularly when navigating funding challenges, with Ian Fisher, head of development analytics.
In this episode of Denatured BioSpace’s head of insights Lori Ellis discusses the public health consequences of vaccine hesitancy and the critical distinction between skepticism and cynicism with Paul Offit, MD, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia.
Webinars
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
BioSpace at 2025 SCOPE Summit
Events
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
- BIO International Convention: June 16-19, 2025 | Boston, MA
- Bioprocessing Summit: August 18-21, 2025 | Boston, MA
- Meeting on the Mesa: October 6-8, 2025 | Phoenix, AZ
BioSpace x DIA
The groundwork being done in 2024 is building the foundation for global collaboration in the future.
DRUG DEVELOPMENT
DRUG DEVELOPMENT
FROM BIOSPACE INSIGHTS
In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses how collaboration and investment shape the the future of women’s health with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.
At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ongoing challenges in manufacturing, distribution, treatment center capacity, and global payment structures for cell and gene therapies.
In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.
Health-focused nonprofits like the Drug Information Association (DIA) serve as crucial bridge-builders in the healthcare ecosystem during a time of uncertainty.
AI offers tremendous potential but there are critical and time-consuming flaws in black box AI predictions.
Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.
In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the evolution of women’s inclusion in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.
In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of inclusion and exclusion criteria of clinical trial patients, and reflect on current investment approaches around women’s health.